吉林敖东药业集团股份有限公司 | 证券代码：000623 | 证券简称：吉林敖东 | 公告编号：2023-062 | | --- | --- | --- | | 债券代码：127006 | 债券简称：敖东转债 | | 关于控股子公司获得药品注册证书的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，吉林敖东药业集团股份有限公司（以下简称"公司"）控股子公司吉 林敖东洮南药业股份有限公司（以下简称"洮南药业"）收到国家药品监督管理 局（以下简称"药监局"）下发的"苹果酸舒尼替尼胶囊"《药品注册证书》。现 就相关情况公告如下： 一、《药品注册证书》的主要内容 1、药品通用名称：苹果酸舒尼替尼胶囊 主要成份：苹果酸舒尼替尼 剂型：胶囊剂 规格：12.5mg（按C22H27FN4O2计） 注册分类：化学药品4类 受理号：CYHS2102310国 证书编号：2023S01349 药品批准文号有效期：至2028年09月04日 上市许可持有人名称：吉林敖东洮南药业股份有限公司 上市许可持有人地址：吉林省洮南经济开发区兴业路2999号 1 药品注册标准 ...

证券代码:000623 证券简称:吉林敖东 债券代码:127006 债券简称:敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-----------------------------------------------------|----------------------------------|-------------------------| | | | | 编号:2023-014 | | | √特定对象调研 □分析师会议 | | | | 投资者关系活动类别 | □媒体采访 □业绩说明会□新闻发布会 □路演活动□现场参观 | | | | | □其他 | (请文字说明其他活动内容) | | | | 网络通讯方式 | | | | | 信达证券:章钟涛 | | | | | 淡水泉(北京)投资管理有限公司:杨烨 | | | | | 广东正圆私募基金管理有限公司:亓辰 | | | | | 嘉实基金:万品玉 | | | | 参与人员及方 | 阳光资管:赵孟甲 | | | | 式 | 永赢基金:陆凯琳 ...

Product Development and Research - The company is developing small-volume injection formulations of L-carnitine to enhance market competitiveness based on market demand[1]. - The company has completed pharmaceutical research for sodium dexamethasone phosphate injection and is undergoing consistency evaluation to expand market share[1]. - The company is conducting consistency evaluation studies for sodium bicarbonate tablets to create a new leading product group and enhance core competitiveness[1]. - The company has completed the verification of production for oxazepam sodium injection and is optimizing detection methods to expand market share[1]. - The company is developing a new product for the treatment of liver failure, acetylcysteine injection, which is currently in the small-scale research phase[1]. - The company has received production approval for a new high-value product, bromide neostigmine injection, aimed at reversing neuromuscular blockade[1]. - The company is conducting clinical trials for the second development of Lingbei cough syrup to provide clinical data support[4]. - The company has established a genetic resource analysis for northern medicinal materials and is developing quality standards for ginseng and epimedium[4]. Financial Performance - Total revenue for the reporting period reached ¥1,583,013,586.76, representing a year-on-year increase of 26.62% compared to ¥1,250,232,567.20[6]. - Revenue from the pharmaceutical sector was ¥1,159,667,639.45, accounting for 73.26% of total revenue, with a year-on-year growth of 23.53%[6]. - Revenue from the food sector surged to ¥204,029,894.40, a remarkable increase of 303.76% from ¥50,532,194.19 in the same period last year[6]. - The gross profit margin for the pharmaceutical sector was 57.52%, slightly down by 1.84% year-on-year[6]. - The company reported a gross profit margin of 36.46% for the food sector, which increased by 15.13% year-on-year[6]. - The company's operating revenue for the first half of 2023 reached approximately CNY 766.25 million, with a net profit of around CNY 155.93 million[19]. - Net profit attributable to shareholders for the current period is ¥1,063,182,266.15, a significant increase of 114.94% from ¥494,642,569.86 in the previous year[43]. - Basic earnings per share for the current period is ¥0.9434, up 117.12% from ¥0.4345 in the previous year[43]. - The company reported non-operating income of CNY 125,119,133.52, which includes gains from the disposal of non-current assets and government subsidies[134]. Investment and Expansion - The company invested ¥16,429,551.30 in the second phase of the expansion project for Jilin Aodong Yanyan Pharmaceutical Co., with a cumulative investment of ¥234,013,305.01[9]. - The automation production line project for Tainang Pharmaceutical has reached 50% completion, with an investment of ¥3,216,498.16 during the reporting period[9]. - The company has established a new partnership with Zhuhai Guangfa Xinde Houze Venture Capital, investing ¥30,000,000.00, holding a 42.86% stake[9]. - The total amount of committed investment projects is CNY 241.3 million, with an actual investment of CNY 238.85 million, achieving an investment progress of 99.4%[26]. - The company plans to invest 97,016.27 million CNY in the expansion and upgrading project of Jilin Aodong Yanyan Pharmaceutical Co., with an expected internal rate of return (after tax) of 17.91% and a payback period of 7.15 years[29]. - The company aims to enhance production capacity and efficiency through the establishment of intelligent production lines for oral liquid products[29]. Operational Efficiency and Production Capacity - The company has completed the construction of the automated production line at Jilin Aodong Tumen Pharmaceutical Co., Ltd., with the new injection line and capsule production line now in operation[3]. - The company has reported that the production capacity of its existing facilities is sufficient to meet current market demands[3]. - The company has completed technical upgrades to its traditional Chinese medicine extraction and solid preparation workshops, which now meet sales demand[3]. - The company is focusing on expanding its production capacity for traditional Chinese medicine formula granules, with a project budget of 4.42 billion yuan allocated for this purpose[194]. - The company is enhancing its marketing strategy by integrating online and offline sales channels, including e-commerce and live streaming[176]. Environmental and Social Responsibility - The company has implemented strict environmental protection measures to comply with regulations and improve operational sustainability[49]. - The company is committed to achieving carbon neutrality and has integrated carbon reduction elements into its production processes[81]. - The company plans to prioritize purchasing raw materials from impoverished areas to support rural revitalization efforts[84]. - The company has invested CNY 2,173,545.85 in environmental governance and protection projects during the first half of 2023, with subsidiaries investing CNY 763,582.76 and CNY 666,200.00 respectively[114]. - The company has established pollution control facilities that are operating effectively, with all major pollutant concentrations meeting environmental requirements[91]. Market and Competitive Landscape - The company is actively participating in the national medical insurance drug list adjustment, which aims to optimize the drug directory structure and improve accessibility for patients[141]. - The company is closely monitoring policies related to traditional Chinese medicine procurement and adjusting its product strategies accordingly[141]. - The company is focusing on three core product categories in traditional Chinese medicine, fostering a multi-product group development strategy[153]. - The national medical insurance drug list was updated, with an average price reduction of 60.1% for newly included drugs, increasing competition in the industry[151]. - The company is expanding its product offerings in the market for traditional Chinese medicine formula granules, having completed 354 product registrations to enhance competitiveness[194]. Risk Management - The company is facing risks in drug development due to long cycles, high investment, and increasing regulatory scrutiny, which may lead to higher costs and extended registration periods[22]. - The company faces systematic risks due to industry policy changes, particularly in the pharmaceutical sector, which is heavily influenced by national policies[45]. - The company plans to maintain a cautious investment strategy to mitigate risks associated with fluctuations in the securities market and changes in capital market policies[50]. - The company emphasizes the importance of risk awareness and has outlined potential risks and mitigation strategies in its report[108].

| 证券代码：000623 | 证券简称：吉林敖东 | 公告编号：2023-055 | | --- | --- | --- | | 债券代码：127006 | 债券简称：敖东转债 | | 吉林敖东药业集团股份有限公司 关于控股子公司获得中药配方颗粒上市备案凭证 的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 未来，公司将严格遵守相关法律法规，结合市场情况开展上述产品的生产、 销售工作。但上述产品的销售情况受市场环境变化等因素的影响，具有不确定性， 预计短期内不会对公司业绩产生重大影响，敬请广大投资者谨慎决策，注意防范 投资风险。 特此公告。 吉林敖东药业集团股份有限公司董事会 2023年8月15日 根据《中华人民共和国药品管理法》《中华人民共和国药品管理法实施条例》 等法律和法规的规定，对延边药业的以下产品予以备案： | 序号 | 名称 | 备案号 | | --- | --- | --- | | 1 | 桃仁（山桃）配方颗粒 | 上市备字2223000089000 | | 2 | 徐长卿配方颗粒 | 上市备字2223000090000 | ...

证券代码：000623 证券简称：吉林敖东 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-----------------------------------------------------|--------------------------------|------------------------------| | | | | 编号：2023-013 | | | √特定对象调研 □分析师会议 | | | | 投资者关系活动类别 | □媒体采访 □业绩说明会□新闻发布会 □路演活动□现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | | 现场会议 | | | | | 天风证券：张中华 | | | | | 广州钜米资本：周宜凯 | | | | 参与人员及方 | 光大证券股份（自营）：邹悦 | | | | 式 | 中国国际金融股份：胡迪 | | | | | 宁波梅山保税港区机缘投资：潘曦明 | | | | | 银华基金：华强强 ...

证券代码：000623 证券简称：吉林敖东 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-----------------------------------------------------|----------------------------------------------|------------------| | | √特定对象调研 □分析师会议 | | | | 投资者关系活动类别 | □媒体采访 □业绩说明会□新闻发布会 □路演活动√现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | 参与人员及方 | 现场参观调研 | | | | 式 | 国泰君安证券投教基地及个人投资者 | | | | 时间 | 2023 年 7 月 19 日 | | | | 地点 | 吉林省敦化市敖东大街 | 2158 号 | | | | 副董事长、总经理：郭淑芹 | | | | 上市公司接待 | 董事、党委书记：赵大龙 | | | | 人员姓 ...

证券代码：000623 证券简称：吉林敖东 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-----------------------------------------------------|----------------------------------------|--------------------------------------| | | | | 编号：2023-010 | | | √特定对象调研 □分析师会议 | | | | 投资者关系活动类别 | □媒体采访 □业绩说明会□新闻发布会 □路演活动□现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | | 现场会议 | | | | 参与人员及方 | | | | | 式 | 平安证券：叶寅、韩盟盟、臧文清 | | | | | 工银瑞信：丁洋、李乾宁 | | | | 时间 | 2023 年 6 月 29 日 | | | | 地点 | 北京金茂威斯汀大酒店 | | | ...

证券代码：000623 证券简称：吉林敖东 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|-----------------------------------------------------|----------------------------------------------| | | √特定对象调研 □分析师会议 | | | 投资者关系活动类别 | □媒体采访 □业绩说明会□新闻发布会 □路演活动□现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | 现场会议 | | | 参与人员及方 | 海通证券：张澄 | | | 式 | 凯丰投资：裴彦春 | | | | 凯石基金：吴蔽野 | | | 时间 | 2023 年 6 月 29 日 | | | 地点 | 合肥洲际酒店 | | | 上市公司接待 | 董事、副总经理：杨凯 | | | 人员姓名 | 董事、副总经理、董事会秘书：王振宇 | | | | 1、公司的背景和组织架构？ | | | | 公 ...

证券代码：000623 证券简称：吉林敖东 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-----------------------------------------------------|----------------------------|--------------------------------------| | | | | 编号：2023-009 | | | √特定对象调研 □分析师会议 | | | | 投资者关系活动类别 | □媒体采访 □业绩说明会□新闻发布会 □路演活动□现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | | 线上调研 | | | | | 中信建投：高庆勇 | | | | | 中邮理财：徐华 | | | | 参与人员及方 | 贝莱德：张万昕 | | | | 式 | 中金资管：柳天慧 | | | | | 东北证券：潘云峰、唐瑜 | | | | | 信达资管：陈巧玲 | | | | | 申万宏 ...

证券代码：000623 证券简称：吉林敖东 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-----------------------------------------------------|---------|------------------| | | √特定对象调研 □分析师会议 | | | | 投资者关系活动类别 | □媒体采访 □业绩说明会□新闻发布会 □路演活动□现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | | 线上调研 | | | | | 中天证券：李琛 | | | | | 国泰产险：干戈 | | | | 参与人员及方 | 永赢基金：陆凯琳 | | | | 式 | 渤海资管：王艺群 | | | | | 兴业研究：华佩琦 | | | | | 国联证券：刘一鸣 | | | | | 华安证券：胡倩倩 | | | | 时间 | 2023 年 6 月 12 日 | | | | 地点 | 吉林省敦化市敖东大街 | 215 ...